pharma · Hypertension · Gastric Ulcer
Yung Shin Pharmaceutical
Yung NA
Yung Shin Pharmaceutical clinical programs — 10 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Taichung, CN
- Founded
- 1952
- Employees
- 264
- Programs
- 10
- Drugs
- 13
- Patents
- 0
Yung Shin Pharmaceutical projects
10 ClinicalTrials.gov programs sponsored by Yung Shin Pharmaceutical.
Yung Shin Pharmaceutical has 10 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Fimasartan and Rosuvastatin
Yung NA
Essential Hypertension, Dyslipidemia
1 trial -
dabigatran
Yung NA
Atrial Fibrillation
1 trial -
Prednisone + Jakavi(ruxolitinib)
Yung NA
GVHD - Graft-Versus-Host Disease
1 trial -
gemcitabine
Yung NA
Muscle Invasive Bladder Urothelial Carcinoma
1 trial -
BRI-1501
Yung NA
Gastric Ulcer
1 trial -
Fimasartan
Yung NA
Hypertension
1 trial -
Fimasartan
Yung NA
Essential Hypertension
1 trial -
Fimasartan/Atorvastatin Combination Tablet
Yung NA
Hypertension
1 trial -
Rabeprazole Sodium 10mg
Yung NA
Gastroesophageal Reflux Disease
1 trial -
Pregabalin
Yung NA
Diabetic Peripheral Neuropathy
1 trial
Frequently asked questions
How many clinical projects does Yung Shin Pharmaceutical have?
10 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.